LY3839840 + midazolam

LY3839840 + midazolam refers to the co-administration of Eli Lilly's LY3839840, an investigational small molecule G protein-coupled receptor 119 (GPR119) agonist, and midazolam, a benzodiazepine that serves as a standard clinical probe for cytochrome P450 3A (CYP3A) enzyme activity. This combination is primarily utilized in Phase 1 clinical pharmacology studies to evaluate the potential for LY3839840 to act as an inducer or inhibitor of CYP3A4/5 metabolism. LY3839840 is being developed for the treatment of metabolic conditions such as type 2 diabetes mellitus, where it aims to enhance glucose-dependent insulin secretion and stimulate the release of incretin hormones like GLP-1 and GIP. Midazolam is included in these studies to ensure that LY3839840 does not adversely affect the pharmacokinetics of other medications metabolized by the same pathway.

Other names

LY3839840 and midazolamLY-3839840 and midazolamLY 3839840 and midazolam